Stocks to buy: ICICI Securities, L&T Technology, Sun Pharma among 5 shares for up to 39% return

Stocks to buy: Brokerage firms have recommended five stocks having the potential to yield up to 39 per cent return to investors. 

ZeeBiz WebTeam | Jan 24, 2023, 09:16 AM IST

Stocks to buy: Brokerage firms have recommended five stocks having the potential to yield up to 39 per cent return to investors. One may consider these recommendations for positive yield.

(Disclaimer: The advice given here to invest in stocks is given by a brokerage house. These are not the views of Zee Business. Consult your advisor before investing.)

1/5

L&T Technology

L&T Technology

L&T Technology

Brokerage firm Motilal Oswal has recommended buying shares of L&T Technology for a target price of Rs 3,940. apiece. On January 20, 2023, the scrip settled at Rs 3,233. In this way, investors can get a return of Rs 707 per share or about 22 per cent. Image source- Pixabay

2/5

Vinati Organics

Vinati Organics

Vinati Organics

Brokerage firm Motilal Oswal has recommended buying shares of Vinati Organics for a target price of Rs 2,740. apiece. On January 20, 2023, the scrip settled at Rs 1,965. In this way, investors can get a return of Rs 775 per share or 39 per cent. Image source- Pixabay

3/5

ICICI Securities

ICICI Securities

ICICI Securities

Brokerage firm Motilal Oswal has recommended buying shares of ICICI Securities for a target price of Rs 610. apiece. On January 20, 2023, the scrip settled at Rs 500. In this way, investors can get a return of Rs 110 per share or 22 per cent. Image source- Pixabay

4/5

AU Small Finance Bank

AU Small Finance Bank

AU Small Finance Bank

Brokerage firm Motilal Oswal has recommended buying shares of AU Small Finance Bank for a target price of Rs 740. apiece. On January 20, 2023, the scrip settled at Rs 615. In this way, investors can get a return of Rs 125 per share or 20 per cent. Image source- Pixabay

5/5

Sun Pharma

Sun Pharma

Sun Pharma

Brokerage firm Motilal Oswal has recommended buying shares of Sun Pharma for a target price of Rs 1,200. apiece. On January 20, 2023, the scrip settled at Rs 1,032. In this way, investors can get a return of Rs 168 per share or 16 per cent. Image source- Pixabay

By accepting cookies, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.

x